1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin, 2016, 66(1): 7-30.
|
2. |
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol, 2007, 608: 1-22.
|
3. |
Siegel RL, Miller KD, Jemal A. Cancer statistics 2019. CA Cancer J Clin, 2019, 69(1): 7-34.
|
4. |
徐冰河, 江泽飞, 胡夕春. 中国晚期乳腺癌临床诊疗专家共识 2016. 中华医学杂志, 2016, 22(96): 1719-1727.
|
5. |
王芳, 郝春芳, 贾勇圣, 等. 205 例初治转移性乳腺癌的临床病理特点和生存分析. 中国肿瘤临床, 2014, 41(17): 1103-1107.
|
6. |
Shim HJ, Kim SH, Kang BJ, et al. Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev, 2014, 15(14): 5539-5544.
|
7. |
Schröder J, Fietz T, Köhler A, et al. Treatment and pattern of bone metastases in 1 094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study. Eur J Cancer, 2017, 79: 139-148.
|
8. |
Martin TJ, Moseley JM. Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer, 2000, 7(4): 271-284.
|
9. |
Selzner M, Morse MA, Vredenburgh JJ, et al. Liver metastases from breast cancer: long-term survival after curative resection. Surgery, 2000, 127(4): 383-389.
|
10. |
Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist, 2003, 8(6): 514-520.
|
11. |
Er O, Frye DK, Kau SW, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer, 2008, 14(1): 62-68.
|
12. |
Aders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer, 2011, 117(8): 1602-1611.
|
13. |
Hatoum HA, Jamali FR, El-Saghir NS, et al. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall suivival in patients with nonmetastatic lymph node-positive breast cancer. Indian J Surg Oncol, 2010, 1(4): 305-312.
|
14. |
乔洪洁, 丛庆华. 乳腺癌与乳腺良性肿瘤患者术前心理社会因素比较. 中国医院统计, 2013, 20(6): 431-433.
|
15. |
Herbert C, Nichol A, Olivotto I, et al. The impact of hypofractionated whole breast radiotherapy on local relapse in patients with Grade 3 early breast cancer:a population-based cohor study. Int J Radiat Oncol Biol Phys, 2012, 82(5): 2086-2092.
|
16. |
淦锦, 黄桂林, 李志刚, 等. 乳腺癌改良根治术后复发转移相关因素. 中华实用诊断与治疗杂志, 2013, 27(1): 33-35.
|
17. |
高鹏, 周庚寅, 魏军民, 等. 乳腺癌 C-erbB2 过表达与生存率、内分泌治疗效果和预后的关系. 中国普通外科杂志, 2003, 10(3): 357-359.
|
18. |
Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. Clin Oncol, 2010, 28(20): 3271-3277.
|
19. |
Staaf J, Ringnér M, Vallon-Christersson J, et a1. Identification of subtypes in human epidermal growth factor receptor 2—positive breast cancer reveals a gene signature prognostic of outcome. Clin Oncol, 2010, 28(11): 1813-1820.
|
20. |
Milanezi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn, 2008, 8(4): 417-434.
|
21. |
汪波, 管忠震, 刘冬耕, 等. 雌、孕激素受体及 HER-2 受体在乳腺癌原发灶及复发转移灶之间的表达差异. 癌症, 2004, 23(12): 1710-1713.
|
22. |
Li ZH, Hu PH, Tu JH, et al. Luminal B breast cancer:patterns of recurrence and clinical outcome. Oncotarget, 2016, 7(40): 65024-65033.
|
23. |
江泽飞, 陈佳艺, 牛晓辉, 等. 乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2014 版). 中华医学杂志, 2015, 95(4): 241-247.
|
24. |
Ozawa H, Sata A, Fukui R. A single-centre, rertrospective observational analysis of fulvestrant for recurrent/metatastaic breast cancer according to metastatic site. Anticancer Res, 2019, 39(11): 5653-5662.
|
25. |
Gennari A, D'amico M, Corradengo D. Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. Ther Adv Med Oncol, 2011, 3(5): 229-232.
|
26. |
周毅, 周勤. 诺维本加铂类二线化疗治疗老年复发转移性乳腺癌的疗效. 中国老年学杂志, 2013, 33(1): 204-205.
|
27. |
夏金, 陈瑞萍, 张彦芳, 等. 诺维本联合铂类二线化疗治疗老年复发转移性乳腺癌的疗效分析. 肿瘤药学, 2015, 5(3): 209-212.
|